[Pregnancy with lupus erythematosus-an update]

Area of Science:

• Obstetrics and Gynecology
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) and pregnancy management requires understanding adverse outcome predictors.
• Hydroxychloroquine (HCQ) safety and efficacy during pregnancy are key research areas.
• Preconception counseling is crucial for optimizing pregnancy outcomes in women with SLE.

Purpose of the Study:

• To review current research on SLE and pregnancy, focusing on predictors of adverse outcomes.
• To highlight the benefits of continuing hydroxychloroquine (HCQ) during pregnancy.
• To summarize evidence-based recommendations for managing SLE and antiphospholipid syndrome during pregnancy.

Main Methods:

• Review of current research and evidence-based recommendations.
• Inclusion of findings from the PROMISSE study on pregnancy outcome predictors.
• Synthesis of data on hydroxychloroquine (HCQ) and low-dose acetylsalicylic acid use.

Main Results:

• The PROMISSE study identifies prospective predictors of adverse pregnancy outcomes in SLE.
• Continuing hydroxychloroquine (HCQ) during pregnancy offers significant benefits.
• Low-dose acetylsalicylic acid is effective in preventing preeclampsia.

Conclusions:

• Continuing HCQ treatment during pregnancy is beneficial for women with SLE.
• Evidence-based guidelines from EULAR aid in managing SLE and antiphospholipid syndrome before, during, and after pregnancy.
• Rheumatologists must stay informed to optimize pregnancy outcomes for SLE patients.